Stem cells and Bronchopulmonary Dysplasia - The five questions: Which cells, when, in which dose, to which patients...

Area of Science:

• Neonatal Medicine
• Regenerative Medicine
• Pulmonology

Background:

• Preterm birth is a leading cause of neonatal mortality.
• Bronchopulmonary dysplasia (BPD) poses significant respiratory risks to premature infants.
• Current BPD treatments are inadequate, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review the potential of mesenchymal stem/stromal cells (MSCs) for treating BPD.
• To address key questions regarding MSC therapy for BPD, including cell source, delivery, and timing.
• To explore the therapeutic mechanisms of MSCs in the context of BPD.

Main Methods:

• Literature review of preclinical and clinical studies on MSCs for BPD.
• Analysis of MSC properties relevant to BPD treatment, such as migration, anti-inflammatory, and regenerative capacities.
• Discussion of ongoing clinical trials and future research directions.

Main Results:

• MSCs from various sources (bone marrow, umbilical cord, placenta) are being investigated for BPD.
• Clinical trials are underway to evaluate MSC efficacy and safety in BPD patients.
• MSCs exhibit promising anti-inflammatory, pro-angiogenic, and tissue-regenerative potentials.

Conclusions:

• MSCs represent a promising therapeutic avenue for bronchopulmonary dysplasia.
• Further research is needed to optimize MSC source, delivery, and timing for BPD treatment.
• Understanding MSC mechanisms is crucial for advancing their clinical application in neonatology.